BlueAllele says rival gained $100m from Regeneron deal using patented tech

Minnesota-based biotech firm says Intellia used its patented gene editing innovations | Regeneron paid Intellia $100m for R&D that infringed three patents, alleges BlueAllele.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

CRISPR

Ricoh strengthens US unit with CRISPR gene editing licence

14 March 2024 Japanese imaging and electronics firm has acquired non-exclusive licence from ERS Genomics | Technology will be used by Elixirgen Scientific, acquired by Ricoh in 2022.

Biotechnology

The new IP battleground in CRISPR-Cas

21 November 2023 Recent clashes over patents covering modified guide RNAs have exposed different approaches from the US and Europe—and new complications for the field, says Claire Irvine of HGF.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

BlueAllele says rival gained $100m from Regeneron deal using patented tech

More on this story

Editor's picks

Editor's picks

More features